













Refractory/Recurrent









 |
Basic Information on
Gemcitabine
Basic Information on Docetaxel
Research Results: Ewing's
Sarcoma
Research Results: non-Ewing's
Sarcoma
-
2000
summary of trial in Israel, stating
that gemcitabine was effective in achieving stabilization of sarcomas
resistant to standard chemotherapies; 8/18
partial, minimal or stable sarcomas. (No Ewing's on study)
-
1999
abstract on gemcitabine for
advanced soft tissue sarcomas; the dosage might have been too low for
response
Current and Closed Clinical
Trials
-
Gemcitabine and docetaxel
Phase 2 trial
at MSK in New York City (another
description) (for adults); Ewing's sarcoma is not allowed
-
Gemcitabine and docetaxel
Phase 1 trial in New Hampshire. The PI was at MSK. The cycles is 2
weeks long; it is a dose-escalation study of docetaxel (for adults)
|